Influence of diet enriched with conjugated linoleic acids on their distribution in tissues of rats with DMBA induced tumors

Abstract

Background: Conjugated linoleic acids (CLA) are a group of positional and geometric isomers of linoleic acid with proven beneficial influence on health. They show e.g. anticarcinogenic, antiobesity, and antiatherogenic effect. Milk, dairy products and meat of poligastric animals are their most valuable dietary sources, with cis-9, trans-11 CLA (RA--rumenic acid) being the predominant isomer. Dietary supplements with CLA became very popular, mainly among the overweight and bodybuilders.The aim of this study was to examine the influence of the food supplements with conjugated linoleic acid on carcinogenesis in female Sprague-Dawley rats and evaluation of CLA and other fatty acids distribution in their bodies.Animals were divided into four groups depending on the diet supplementation (oil or Bio-C.L.A. (Pharma Nord Denmark) given intragastrically) and presence or absence of carcinogenic agent (7,12-dimethylbenz[a]antharcene). Animals were decapitated at 21st week of experiment and serum and microsomes were extracted.

Results and conclusions: The mammary tumours (adenocarcinoma) occurred in groups treated with DMBA. Diet enriched with CLA decreased the cancer morbidity (67% in Bio-C.L.A. compared to 88% in oil) and delayed the cancer induction (p = 0.0018). There were no differences in body and organs weight.The supplement used in the study was a mixture of several fatty acids with the greatest proportion of CLA isomers: trans-10, cis-12 (33%) and cis-9, trans-11 (31%). Both of them were present in tissues but the content of rumenic acid was greater. Dietary supplementation had also significant impact on other fatty acids content, both in serum and in microsomes.

Figure 1

Fatty acids composition of experimental diets (% of total fatty acids).

Figure 2

Content of cis-9, trans-11 CLA in serum and microsomes of individuals with or without tumours.

Figure 3

Content of trans-10, cis-12 CLA in serum and microsomes of individuals with or without tumours.

Figure 4

Content of cis-9, trans-11 CLA in serum of B1 individuals with or without tumours.

Figure 5

Content of cis-9, trans-11 CLA in microsomes of B1 individuals with or without tumours.